2019-02-04 15:16 ET - Cease Trade/Suspend Company

CSE bulletin 2019-0206

Abattis Bioceuticals Corp. is in default of Canadian Securities Exchange requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a regulatory halt as defined in National Instrument 23-101 trading rules.

A cease trade order has been issued by the Ontario Securities Commission and the British Columbia Securities Commission.

Date: Feb. 4, 2019

Symbol: ATT